Skip to main content

Table 1 Association of MACC1 SNPs with clinicopathological factors

From: SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer

rs4721888 (L31V)      
Parameters Leu/Leu (ctc/ctc) (%) Leu/Val (ctc/gtc) (%) P-value OR 95% CI
All tumors, n = 154 134 (87%) 20 (13%)    
Metachronous metastasis,n = 29 27 (93%) 2 (7%) 0.28 0.44 0.10 - 2.02
Gender male, n = 79 68 (86%) 11 (14%) 0.72 1.19 0.46 - 3.05
Age > 66.32 years (median),n = 77 67 (87%) 10 (13%) 1.00 1.00 0.39 – 2.56
pT3 and pT4, n = 118 102 (86%) 16 (14%) 0.70 1.26 0.39 - 4.03
N1 to N3, n = 53 43 (81%) 10 (19%) 0.12 2.12 0.82 - 5.47
UICC stage I, n = 26 24 (92%) 2 (8%) 0.38 0.51 0.11 - 2.34
UICC stage II, n = 74 66 (89%) 8 (11%) 0.44 0.69 0.26 - 1.79
UICC stage III, n = 54 44 (81%) 10 (19%) 0.13 2.05 0.79 - 5.28
rs975263 (S515L)      
Parameters Ser/Ser (tcg/tcg) (%) Ser/Leu (tcg/ttg) (%) P-value OR 95% CI
All tumors, n = 154 80 (52%) 74 (48%)    
Metachronous metastasis,n = 29 12 (41%) 17 (59%) 0.21 1.69 0.75 – 3.83
Gender male, n = 79 40 (51%) 39 (49%) 0.74 1.11 0.59 - 2.10
Age > 66.32 years (median),n = 77 40 (52%) 37 (48%) 1.00 1.00 0.53 – 1.88
pT3 and pT4, n = 118 63 (53%) 55 (47%) 0.52 0.78 0.37 - 1.65
N1 to N3, n = 53 26 (49%) 27 (51%) 0.60 1.19 0.61 - 2.32
UICC stage I, n = 26 14 (54%) 12 (46%) 0.83 0.91 0.39 - 2.13
UICC stage II, n = 74 39 (53%) 35 (47%) 0.86 0.94 0.50 - 1.78
UICC stage III, n = 54 27 (50%) 27 (50%) 0.72 1.13 0.58 - 2.19
rs3735615 (R804T)     without R804T compared to with R804T
Parameters Arg/Arg (aga/aga) (%) Arg/Thr (aga/aca) (%) Thr/Thr (aca/aca) (%) P-value OR 95% CI
All tumors, n = 154 25 (16%) 74 (48%) 55 (36%)    
Metachronous metastasis,n = 29 5 (17%) 15 (52%) 9 (31%) 0.95 0.96 0.33 - 2.80
Gender male, n = 79 11 (14%) 37 (47%) 31 (39%) 0.43 1.42 0.60 - 3.36
Age > 66.32 years (median),n = 77 12 (16%) 39 (51%) 26 (34%) 0.83 1.10 0.47 - 2.59
pT3 and pT4, n = 118 21 (18%) 53 (45%) 44 (37%) 0.34 0.58 0.18 - 1.81
N1 to N3, n = 53 9 (17%) 27 (51%) 17 (32%) 0.86 0.92 0.38 - 2.25
UICC stage I, n = 26 4 (15%) 14 (54%) 8 (31%) 0.90 1.08 0.34 - 3.46
UICC stage II, n = 74 12 (16%) 32 (43%) 30 (41%) 1.00 1.00 0.43 - 2.36
UICC stage III, n = 54 9 (17%) 28 (52%) 17 (32%) 0.91 0.95 0.39 - 2.33
  1. SNPs are not associated with clinicopathological data like metachronous development of distant metastases, gender, age (median: 66.32 years), tumor stages (pT3, pT4), lymph node status (N1 to N3: with lymph node metastases) and UICC stages. Ser: serine, Leu: leucine, Arg: arginine, Thr: threonine. P-values were determined by using Chi-Square test and odds ratios (OR) with 95% confidence intervals (95% CI) were calculated.